文献速递治疗药物监测与药物基因组学特殊人群用药

肾移植受者外周血单个核细胞中他克莫司浓度监测研究

Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients.
PubMed 文献 · Br J Clin Pharmacol · 2020-11-24

该前瞻性研究纳入175例肾移植受者,在术后3、6、12个月测定全血和他克莫司外周血单个核细胞内浓度,并检测ABCB1、CYP3A4、CYP3A5基因型。结果发现全血与细胞内浓度相关性差,年龄、白蛋白和红细胞压积与细胞内/全血比值相关,但两者均与临床结局无关。

要点

  • 全血与他克莫司细胞内浓度相关性差,r=0.31~0.61。
  • 年龄、白蛋白、红细胞压积与细胞内/全血比值相关。
  • 全血和细胞内浓度均与排斥、肾毒性等临床结局无关。

核心结论

  • 全血与他克莫司外周血单个核细胞内浓度相关性差。
  • 年龄、白蛋白和红细胞压积与细胞内/全血比值相关,ABCB1、CYP3A4和CYP3A5基因变异不影响该比值。
  • 全血和细胞内他克莫司浓度均与临床结局无关。

研究设计与样本

  • 前瞻性队列研究,纳入175例肾移植受者。
  • 术后3、6、12个月测定全血和他克莫司外周血单个核细胞内浓度。
  • 检测ABCB1 1199G>A、3435C>T,CYP3A4 15389C>T,CYP3A5 6986G>A基因型。

主要发现

  • 全血与细胞内他克莫司浓度相关性中等至差,第3、6、12个月Spearman r分别为0.31、0.41、0.61。
  • 细胞内/全血比值中位患者内变异为39.0%,范围3.5%~173.2%。
  • 年龄、白蛋白和红细胞压积与细胞内/全血比值相关。
  • CYP3A5和CYP3A4基因型联合影响剂量校正的全血和细胞内他克莫司浓度。
  • ABCB1基因型与他克莫司分布无显著相关。

关键数值与推荐

  • 全血与细胞内他克莫司浓度相关性:Spearman r=0.31(第3个月)、0.41(第6个月)、0.61(第12个月)。
  • 细胞内/全血比值中位患者内变异39.0%,范围3.5%~173.2%。

临床怎么用

  • 目前全血他克莫司浓度监测仍是标准实践,细胞内浓度监测的临床价值尚未确立。
  • 年龄、白蛋白和红细胞压积可能影响他克莫司的细胞分布,临床解读浓度时需考虑。
  • CYP3A5和CYP3A4基因型可影响剂量校正浓度,但ABCB1基因型无显著影响。

局限性

  • 研究未发现全血或细胞内他克莫司浓度与临床结局相关,监测细胞内浓度的获益仍需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Tacrolimus is a critical dose drug and to avoid under- and overexposure, therapeutic drug monitoring is standard practice. However, rejection and drug-related toxicity occur despite whole-blood tacrolimus pre-dose concentrations ([Tac]blood ) being on target. Monitoring tacrolimus concentrations at the target site (within peripheral blood mononuclear cells; [Tac]cells ) may better correlate with drug-efficacy. The aim of this study was to (1) investigate the relationship between [Tac]blood and [Tac]cells , (2) identify factors affecting the tacrolimus distribution in cells and whole-blood, and (3) study the relationship between [Tac]cells and clinical outcomes after kidney transplantation. METHODS: A total of 175 renal transplant recipients were prospectively followed. [Tac]blood and [Tac]cells were determined at Months 3, 6 and 12 post-transplantation. Patients were genotyped for ABCB1 1199G>A and 3435C>T, CYP3A4 15389C>T, and CYP3A5 6986G>A. Data on rejection and tacrolimus-related nephrotoxicity and post-transplant diabetes mellitus were collected. RESULTS: Correlations between [Tac]blood and [Tac]cells were moderate to poor (Spearman's r = 0.31; r = 0.41; r = 0.61 at Months 3, 6 and 12, respectively). The [Tac]cells /[Tac]blood ratio was stable over time in most patients (median intra-patient variability 39.0%; range 3.5%-173.2%). Age, albumin and haematocrit correlated with the [Tac]cells /[Tac]blood ratio. CYP3A5 and CYP3A4 genotype combined affected both dose-corrected [Tac]blood and [Tac]cells . ABCB1 was not significantly related to tacrolimus distribution. Neither [Tac]blood nor [Tac]cells correlated with clinical outcomes. CONCLUSIONS: The correlation between [Tac]blood and [Tac]cells is poor. Age, albumin and haematocrit correlate with the [Tac]cells /[Tac]blood ratio, whereas genetic variation in ABCB1, CYP3A4 and CYP3A5 do not. Neither [Tac]blood nor [Tac]cells correlated with clinical outcomes.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Francke MI, Hesselink DA, Li Y, et al. Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients. Br J Clin Pharmacol. 2020. PMID: 33025649. doi:10.1111/bcp.14585

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。